Drug Shortage Compounding Patient Access Act of 2025
HB5316, titled the Drug Shortage Compounding Patient Access Act of 2025, would amend the Federal Food, Drug, and Cosmetic Act to expand when compounded drugs may be prepared and distributed during shortages or urgent clinical need. The bill creates a new pathway for licensed pharmacists and physicians to compound limited quantities of a drug for urgent administration in a hospital or other clinical setting, even without an identified individual patient prescription, if the drug recently appeared on the FDA shortage list and the prescriber certifies that commercially available or outsourcing-facility versions could not be obtained to meet the urgent need. It also requires specific labeling, packaging notices, patient-tracking documentation, and adverse-event reporting to FDA.
The bill also broadens and clarifies federal drug-shortage reporting rules. It would require manufacturers to report not only discontinuances and manufacturing interruptions, but also surges in demand that may cause shortages, and it revises the statutory definition of shortage to focus on demand exceeding supply while considering dosage form, route of administration, and information from manufacturers, clinicians, and patients. In addition, it makes changes to outsourcing facility compounding rules, updates the treatment of bulk drug substances, and standardizes labeling for compounded drugs to make clear that they are not FDA-approved.
If enacted, the bill would amend sections 503A, 503B, 506C, and related provisions of the Federal Food, Drug, and Cosmetic Act, directly affecting pharmacy compounding, outsourcing facilities, and FDA shortage reporting. It would give hospitals and clinical settings more flexibility to obtain compounded medications during shortages or urgent situations, while imposing documentation, labeling, and adverse-event reporting requirements on compounders. The bill would also expand manufacturer reporting obligations and alter the legal definition of drug shortage and surge in demand, potentially affecting FDA oversight, supply-chain monitoring, and how shortages are identified and managed.
Based on the bill text and available context, the overall sentiment appears supportive of improving patient access to needed medications during shortages. The measure was introduced by bipartisan sponsors and referred to committee without recorded votes or hearing testimony in the provided materials, so there is no documented opposition or amendment debate in the record here. The bill’s framing emphasizes access, urgency, and shortage mitigation rather than restriction.
The main policy tension in the bill is between expanding access to compounded drugs and preserving safeguards around compounding and FDA-approved products. Potential concerns include whether allowing limited non-patient-specific compounding for urgent hospital use could blur the line between traditional pharmacy compounding and drug manufacturing, and whether the new shortage and surge reporting requirements would impose additional compliance burdens on manufacturers. Another possible point of contention is the bill’s reliance on prescriber certification, patient record linkage, and adverse-event reporting as safeguards, which may be viewed as either sufficient protections or as administratively complex depending on stakeholder perspective.